Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
ConditionMultiple Sclerosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-60
SponsorOndokuz Mayıs University
About this trial
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
Eligibility criteria
Qualifiers
Confirmed diagnosis of MS
Progressive type MS
Voluntary participation
Age between 18-60 years
Disqualifiers
Presence of another neurological disorder
Change in medication within the last 3 months
Relapse within the last 3 months
Trial design
Treatments tested in this trial
- Not listed
Trial groups
22 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov